ACYLINE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C80H102ClN15O14
Molecular Weight	1533.211
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(C)=O)C=C1)NC(=O)[C@H](CC2=CC=C(NC(C)=O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(Cl)C=C4)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N7CCC[C@H]7C(=O)N[C@H](C)C(N)=O

InChI

InChIKey=ZWNUQDJANZGVFO-YHSALVGYSA-N

InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,70+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C80H102ClN15O14
Molecular Weight	1533.211
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	4
Optical Activity	UNSPECIFIED

Description
Sources: http://mct.aacrjournals.org/content/6/11_Supplement/B83 | https://www.ncbi.nlm.nih.gov/pubmed/15579744 | https://adisinsight.springer.com/drugs/800025851

Merrion Pharmaceuticals was developing an oral tablet formulation of acyline, a gonadotropin-releasing hormone (GnRH) antagonist, referred to as MER 104. MER-104 effectively suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in man. Acyline has been investigated for the prevention and treatment of hypogonadism and contraception. Injectable forms have been administered successfully in man in Phase II studies as part of a potential contraceptive regimen. MER-104 is an enteric coated acyline tablet developed by Merrion Pharmaceuticals using GIPET™ I technology to enable the oral administration of this decapeptide. The development of acyline appears to have been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.	2004 Dec	15579744
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.	2006 May	16352669
Insights into male germ cell apoptosis due to depletion of gonadotropins caused by GnRH antagonists.	2007 Jun	17268770

Sample Use Guides

In Vivo Use Guide

Prostate cancer :10, 20 and 40 mg doses of GIPET-enhanced oral acyline

Route of Administration: Oral

In Vitro Use Guide

Acyline had antagonistic potency IC50 = 0.52 nM

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:52:52 GMT 2023` Edited by `admin` on `Fri Dec 15 15:52:52 GMT 2023`
Record UNII	S3439D3B35
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACYLINE

Common Name

English

D-ALANINAMIDE, N-ACETYL-3-(2-NAPHTHALENYL)-D-ALANYL-4-CHLORO-D-PHENYLALANYL-3-(3-PYRIDINYL)-D-ALANYL-L-SERYL-4-(ACETYLAMINO)-L-PHENYLALANYL-4-(ACETYLAMINO)-D-PHENYLALANYL-L-LEUCYL-N6-(1-METHYLETHYL)-L-LYSYL-L-PROLYL-

Systematic Name

English

MER-104

Code

English

Code System Code Type Description

EPA CompTox

DTXSID60168812